Atossa Genetics (NASDAQ:ATOS)‘s stock had its “buy” rating reaffirmed by Maxim Group in a report released on Wednesday. They presently have a $5.00 price target on the stock. Maxim Group’s price objective points to a potential upside of 249.65% from the company’s previous close.
The analysts wrote, “Atossa announced that the preliminary results (PK, tolerability, safety) reported in 3Q18 in the P1 study of topical Endoxifen in male healthy subjects are now final. The company is awaiting the completion of an ongoing P2 study in women with mammographic breast density (MBD, expected 2Q19) to determine the next steps clinically for developing topical Endoxifen in men with breast health issues, including gynecomastia.””
Shares of ATOS stock opened at $1.43 on Wednesday. Atossa Genetics has a 1 year low of $0.80 and a 1 year high of $10.68.
Atossa Genetics (NASDAQ:ATOS) last issued its earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.01. Research analysts anticipate that Atossa Genetics will post -4.31 EPS for the current fiscal year.
About Atossa Genetics
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.